Healthcare hedge fund Rhenman rises 12 per cent this year, as biotech and pharma bets drive June returns Submitted By Hugh Leask | 12/07/2021 - 12:14pm Healthcare-focused equity hedge fund Rhenman & Partners scored a near-12 per cent return in the first six months of the year, as a number of correct calls in biotechnology and pharmaceuticals stocks drove gains in June. The Stockholm-based manager’s flagship strategy rose 5 per cent last month overall.